Edinburgh life sciences spin-out raises £2.8m

Published: 30 October 2019

A University of Edinburgh spin-out has raised almost £2.8 million to prepare for clinical trials and commercialisation of its “potentially life-saving” technology.

Invizius, which has developed technology to help reduce the high death rate among patients using dialysis and other extra-corporeal treatments, secured the seven-figure sum from a consortium led by asset manager Mercia.

This investment allows us to take a big step towards this, and we are delighted to have won the backing of a consortium of smart, well-funded investors...

Richard Boyd, co-founder and chief executive, Invizius


The funding boost will support pre-clinical testing and manufacturing of the medtech’s product, and help it prepare to enter clinical trials. It plans to hold a further funding round within 18 months.

The spin-out believes its technology, which stems from research by co-founder and chief technology officer Andy Herbert, can reduce the “huge” death toll from cardiovascular disease among long-term dialysis patients. 

The technology can also be used in conjunction with devices such as heart and lung machines, stents and grafts or in organ and cell transplants...

Full story via Edinburgh Evening News


Latest tweets

follow us @InvestEdinburgh